Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial)

percentage of patient with osteoporosis defined by WHO definition with T score

percentage of patients with fragility fractures

scores at questionnaire on quality of life EQ5D = EuroQol 5 dimension 5 L; (min 1-1-1-1-1, max 5-5-5-5-5 higher score worse + EQ VAS min 0, max 100 higher score better quality of life)

scores in fatigue as for questionnaire FACIT-F (Functional Assessment of Chronic Illness Therapy - Fatigue; min 0 - max 52, higher score less fatigue)

scores on quality of life with SF36 v2 (Short Form 36 version 2 Health Survey; min 0 - max 100, higher score better health)

scores on mood disorder scale HADS (Health Anxiety and Depression Scale; min 0 - Max 42, higher score worse anxiety)

compliance questionnaire in rheumatology 5 items; adherent - not adherent to medication)

Patient global assessment ( VAS scale 0-10) higher score worse health

The population will be analyzed grouping by presence or absence of fragility fracture in relation to medications variables such as difference in cumulative corticosteroid dose (mg)

The population will be analyzed grouping by presence or absence of fragility fracture in relation to medications variables such as difference in percentage of hydroxychloroquine users.

The population will be analyzed grouping by presence or absence of fragility fracture in relation to medications variables such as difference in percentage percentage of immunosuppressant users

The population will be analyzed grouping by presence or absence of fragility fracture in relation to medications variables such as difference in percentage of percentage of biologics ( e.g. belimumab) users.

The population will be analyzed as whole and also grouping by presence or absence of fragility fracture in relation to clinical variables - SLE disease duration

The population will be analyzed as whole and also grouping by presence or absence of fragility fracture in relation to clinical variables - SDI ( SLICC Damage index - from 0, higher score higher disease damage accrual)

The population will be analyzed as whole and also grouping by presence or absence of fragility fracture in relation to demographic variable - Age ( years)

The population will be analyzed as whole and also grouping by presence or absence of fragility fracture in relation to demographic variable - gender ( % females)

bone alkaline phosphatase (BAP) (ug/L) level in study population and difference by fracture status

N-terminal propeptide of type I procollagen - P1NP (ng/ml) level in study population and difference by fracture status

C-terminal telopeptide of type I collagen (CTX) (ng/ml), level in study population and difference by fracture status

parathormone (PTH) pg/ml level in study population and difference by fracture status

25OH vitamin D (ng/ml), level in study population and difference by fracture status

sclerostin (pmol/L) level in study population and difference by fracture status

Dkk1 (pmol/L) level in study population and difference by fracture status

RANKL (pg/ml) level in study population and difference by fracture status

OPG (pg/ml level) in study population and difference by fracture status

FRAX fracture risk assessment ( % risk major fracture in 10 yrs)

DEFRA fracture risk assessment ( % risk major fracture in 10 yrs)